The U.S. FDA has granted approval for Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), developed by Eli Lilly and Company.

Eirion Therapeutics Inc. has reported the enrollment of the initial participant in a Phase 1 clinical study aimed at assessing the safety of their proprietary topical medication, ET-02, for the treatment of androgenic alopecia.

KaliVir Immunotherapeutics Receives FDA Approval for Investigational New Drug VET3-TGI in Solid Tumor Immunotherapy.

Idorsia’s JERAYGO (aprocitentan) approved in Europe as the first and only ERA for resistant hypertension treatment.

TauRx Pharmaceuticals Ltd has revealed the filing of a Marketing Authorisation Application in the UK for hydromethylthionine mesylate (HMTM).

Formycon AG, together with their licensing partner Klinge Biopharma GmbH, has disclosed that the FYB203/AHZANTIVE (aflibercept-mrbb), a biosimilar to Eylea, has received approval from the U.S. Food and Drug Administration.

Ubix Therapeutics and Yuhan unveil an exclusive licensing deal for UBX-103, an oral AR degrader to treat metastatic castration-resistant prostate cancer.

The European Union has approved the world's first Sanofi and Regenerant drug, dulprizumab, targeting IL-4Rα for COPD treatment.

Pierre Fabre Laboratories have received European marketing approval for OBGEMSA™ (vibegron) to treat overactive bladder.

KBio Receives FDA IND Approval for EV68-228-N to Treat Acute Flaccid Myelitis and Begins Phase 1 Trial with First Patient Dosed.

GT Biopharma Gets FDA Approval for IND Application for GTB-3650, an NK Cell Engager Targeting CD33+ Leukemia.

Elicio Therapeutics Presents Initial Disease-Free Survival Data from the Phase 1a AMPLIFY-7P Study of ELI-002 7P.